ConcertAI is a Cambridge, Massachusetts company that combines real-world clinical, genomic, imaging, and claims data with applied AI to accelerate cancer research and clinical development. Through its CARA AI platform, large independent oncology data network, and Digital Trial Solutions, it helps biopharma companies, healthcare providers, and medical societies design smarter trials, match patients faster, and generate evidence on how treatments perform outside controlled studies.
Jeff Elton, Ph.D., is the founding CEO and now Vice Chairman of ConcertAI, a Cambridge-based company building generative and predictive AI on the world's largest multi-modal oncology dataset. He grew the company from a 2017 startup into a roughly $1.9 billion business with about 1,300 employees, acquiring TeraRecon's imaging technology and ASCO's CancerLinQ network along the way. A former Accenture managing director, Novartis research COO, and McKinsey partner, he co-authored the widely cited book Healthcare Disrupted and chairs the MassBio board.